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Abstract
Background
The etiology and prognosis of acute liver failure (ALF) remains unknown in a significant 
proportion of cases. Signs of autoimmunity may be present, but no consistent pattern has been 
observed. We aimed to analyse if pretransplant immunological findings, HLA haplotypes and 
clinical features among patients with unknown etiology differ from those of autoimmune or other 
known etiology. We also analysed whether such signs impact post-transplant biopsy findings or 
complications.
Methods
All adult ALF patients undergoing liver transplantation (LT) in Finland during 1987-2015 were 
followed to 2016. Data were from the LT registry, pathology database and patient records. 124 
patients were included in the analysis. Study subgroups were acute autoimmune hepatitis (AIH) 
(n=25), known non-AIH etiology (n=54), and unknown etiology (n=45).
Results
The unknown etiology group differed from the known non-AIH group with regard to the following 
pretransplant autoimmunity-associated features: positive pANCA (35% vs 8%; P=0.02), higher 
mean IgA (3.2±1.7 vs 2.1±1.4, P=0.006) and IgG (12.7±4.3 vs 8.5±3.6, P=0.001). AIH-associated 
HLA haplotypes B8, DR3 and B8DR3 were more common in the AIH group (40%, 44% and 
36%) and in the unknown group (29%, 33% and 29%) than in the known non-AIH group (11%, 
17% and 11%) or in the Finnish general population (17%, 18% and 8%). However, these findings 
had no association with protocol biopsies, extrahepatic autoimmune diseases or survival. Patients 
with ≥1 rejection episode had higher pretransplant IgA (3.7±2.3 vs 2.6±1.2, P=0.02) and IgG 
(16.4±10.2 vs 12.4±6.8, P=0.03) than those without rejections.
Conclusions
Autoimmunity-associated pretransplant laboratory findings and HLA haplotypes were common in 
ALF of unknown etiology, but showed minimal predictive value for post-transplant biopsy 
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Main body text
Introduction
Acute liver failure (ALF) is a severe clinical syndrome characterized by impaired liver function, 
coagulopathy and encephalopathy (1) without pre-existing liver disease. ALF accounts for 8% of 
all liver transplantations in Europe (ELTR 2018) and 3% in United States (OPTN 2017 annual 
report). 
ALF can be caused by various etiologies. Still, despite careful evaluation, the etiology of acute 
liver failure remains unknown in a significant proportion of patients. Studies have so far failed to 
identify novel viral etiology (2,3). Association of ALF of unknown etiology with specific HLA-
haplotypes, female predominance and unspecific autoantibodies may suggest autoimmune etiology 
(4-7).  Autoimmune hepatitis (AIH) can manifest as acute liver failure (8-10), and autoimmune 
hepatitis may be the cause in some of these previously unknown ALFs (11). However, diagnosis in 
this setting is difficult as there are no established diagnostic criteria for AIH-ALF.  
It is unclear whether the unspecific elevations of autoantibodies and immunoglobulins observed in 
many patients with ALF (6) indicate autoimmune etiology or if they are just an epiphenome of the 
immunologic processes triggered by ALF (12).  AIH is known to recur after liver transplantation 
in 17-33% of patients depending on the duration of follow-up and diagnostic criteria, and recurrent 
AIH may lead to graft loss (13). If ALF of unknown etiology has autoimmune background, disease 
recurrence would be expected after transplantation in a significant proportion of patients. Some 
studies have demonstrated an increased prevalence of chronic hepatitis at one year in the group 
with unknown etiology compared to known non-autoimmune etiologies, but few studies with 
protocol biopsies exist (5,11,14).
The aim of the present study was to analyze whether signs of autoimmunity (autoimmune 
serology, HLA-haplotype, and clinical history) differ between ALF of known and unknown cause, 
and whether such signs of autoimmunity predict post-transplant liver protocol biopsy findings, 
rejections or survival. We reviewed all adult patients transplanted for ALF in Finland (since the 
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Materials and methods
Patients
All liver transplantations in Finland are performed at Helsinki University Hospital. We identified 
all adult patients who had been transplanted for ALF in Finland between 1987 and 2015 (N = 152) 
from the liver transplant registry. Data were collected from the transplant registry and patient 
records. All patients included had ALF with encephalopathy and coagulopathy and were 
transplanted within 26 weeks of diagnosis.
The etiology of ALF was determined based on patient’s medical history, laboratory and histology 
data, including the histology of the explanted liver. Patients were considered to have AIH-ALF if 
they fulfilled criteria for probable or definite AIH according to simplified criteria for the diagnosis 
of AIH (SCD-AIH) (15).
Clinical data
Patient records were reviewed for possible extra-hepatic autoimmune diseases in the medical 
history or during the follow-up. We recorded laboratory values and immunosuppressive 
medication at annual visits and at the time of liver biopsy.
All patients received calcineurin inhibitor (CNI)-based immunosuppression; cyclosporin (CYA) 
was slightly more common than tacrolimus (TAC) (latest immunosuppression used). CNI was 
combined with an antimetabolite, azathioprine (AZA) or mycophenolate mofetil (MMF) in most 
cases. All patients received methylprednisolone (MP), which was usually tapered off after the first 
post-transplant year. There were no significant differences in immunosuppression between 
etiological groups at 1, 5 or 10 years (Supplement table 1).
Laboratory data
Laboratory testing to evaluate the etiology of ALF at the transplantation center included hepatitis 
A IgM and IgG antibodies, hepatitis B surface antigen, core antibody and DNA, hepatitis C virus 
antibodies and RNA, hepatitis E IgM and IgG antibodies, cytomegalovirus IgM and IgG 
antibodies and DNA, Ebstein-Barr virus IgM and IgG antibodies and DNA , antinuclear antibodies 
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(SMA), anti-mitochondrial antibodies (AMA), liver and kidney microsomal antibodies (LKM), 
immunoglobulins A, M and G (IgA, IgM, IgG) and human immunodeficiency virus antigen and 
antibodies. Diagnostic tests for Wilson’s disease were made with a low threshold on clinical 
suspicion.
HLA haplotypes B8, DR3, DR4 and DR13 are associated with autoimmune hepatitis in Northern 
Europe (16,17) and homozygosity for B8-DR3 and A1-B8-DR3 have been associated with non-A, 
non-B ALF (4). We evaluated the presence of these HLA haplotypes in our patients and compared 
this to that reported in the Finnish general population (18). The prevalence of HLA B8-DR3 was 
received from the Finnish Red Cross Blood Service (unpublished).
Histological data
Data of possible pretransplant biopsy and histology of the explanted liver were used to evaluate 
the etiology of ALF. Post-transplant histological data comprised evaluation of all post-
transplantation liver biopsies. Biopsies are routinely reviewed at multidisciplinary meetings by an 
experienced liver pathologist and reported structurally. Portal inflammation (graded 0-3), lobular 
inflammation (graded 0-2), interface inflammation (graded 0-3) and fibrosis (graded 0-4) were 
graded according to METAVIR (19). Indication biopsies were performed following unclear 
abnormalities in liver biochemistry after transplantation. All rejections were biopsy-confirmed 
according to Banff criteria (20). Protocol biopsies were started at 2009: at 1 year and 5 years post-
transplant and every 5 years thereafter. Protocol biopsies were performed in all patients after 2009, 
also on those transplanted before 2009.
Graft hepatitis was diagnosed in the presence of portal inflammation combined with lobular or 
interface inflammation without characteristics of other defined pathologies (acute or chronic 
rejection, viral infection or steatohepatitis) (21). The diagnosis of de novo or recurrent AIH was 
based on liver histology typical to AIH with plasma cell-rich hepatitis. Autoantibodies or 
immunoglobulins were not routinely monitored after transplantation.
Statistical analysis
Statistical analysis was performed using SPSS (version 24). Categorical variables were analyzed 
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test. Survival was analyzed using Kaplan Meier method and compared with log rank test. P values 
< 0.05 were considered significant. 
Results
Pre-transplant findings
Patient characteristics and baseline laboratory data are presented in Table 1. Etiologies comprised 
25 AIH, 54 known non-AIH and 45 patients with unknown etiology. Patients with incomplete data 
to confirm the diagnosis (N = 28) were excluded from the analysis.
Known non-AIH etiologies included Budd Chiari syndrome (n = 11), acetaminophen over-dose (n 
= 5), non-acetaminophen drug-induced liver injury (n = 19), acute hepatitis B (n = 5), amanita 
poisoning (n = 5) and miscellaneous (n = 9; trauma, post-operative, lymphoma, EBV, pregnancy-
induced rupture). In case of non-acetaminophen drug-induced liver injury only a definite or very 
likely association was considered as known etiology.
Patients with SCD-AIH score ≥ 6 were classified as AIH. AIH patients had positive ANA titers ≥ 
1:80 (23/25) and/or SMA titers ≥ 1:40 (11/25), elevated IgG > 15 g/l (23/25), negative viral 
serology and no other evident etiology. Only eight of these patients were considered to have 
histology typical to AIH and most had only unspecific histology. Unknown etiology included all 
the patients without a defined etiology.
Compared to patients with known non-AIH etiology, patients with unknown etiology had more 
often pANCA titres ≥ 1:10 (36% vs 8%, P = 0.02), IgA above ULN (27% vs 7%, P = 0.04), IgG 
above ULN (20% vs 0%, P = 0.04). Unknown group had also higher SCD-AIH scores (3.1 ± 1.0 
vs 2.4 ± 1.0, P = 0.005), higher IgA (3.2 ± 1.7 vs 2.1 ± 1.4, P = 0.001) and higher IgG (12.7 ± 4.3 
vs 8.5 ± 3.6, P = 0.001). The known non-AIH group had more often hyperacute presentation and 
they were transplanted faster (22 ± 24 days) than AIH patients (38 ± 36 days) and unknown 
patients (32 ± 35 days), P = 0.02. 
We compared hyperacute, acute and subacute patients in the unknown group and they had similar 
autoantibodies, HLA haplotypes, rejections and survival (data not shown). Patients with subacute 
presentation had higher IgG than acute or hyperacute patients (14.7 ± 3.7 vs 12.1 ± 4.4 vs 9.7 ± 
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Pretransplantion liver biopsy was available in 48/124 (39%) patients. Four biopsies showed 
histology typical to AIH and most biopsies (26/48, 54%) revealed only unspecific inflammation 
and necrosis. Histology of the explanted liver was available in all patients. Nine patients showed 
histology typical to AIH and again, unspecific necrosis (mean level of necrosis 73%, no difference 
between groups) was the most common histological finding (83/124, 67%). Histological 
evaluation of the explanted livers is presented in Supplement table 2.
HLA
There were significant differences in the presence of HLA haplotypes B8, DR3 and B8DR3 
between different etiology groups and the Finnish general population (Table 2). These haplotypes 
were common in the AIH group (B8 40%, DR3 44% and B8DR3 36%) and in the unknown group 
(B8 29%, DR3 33%, B8DR3 29%). The unknown group had these haplotypes significantly more 
often than known non-AIH group (B8 29% vs 11%, P = 0.04; B8DR3 29% vs 11%, P = 0.04) or 
the Finnish general population (B8 29% vs 17%, P = 0.04; DR3 33% vs 18%, P = 0.02; B8DR3 
29% vs 8%, P = 0.001). However, only the difference between the presence of B8DR3 in the 
unknown group and the Finnish general population remained statistically significant when 
Bonferroni correction was applied. Haplotypes DR4 and DR13 were equally distributed among 
groups. No haplotype differed between the known non-AIH group and the Finnish general 
population.
We compared these HLA haplotypes with pretransplant laboratory test and found that DR4 was 
associated with higher IgM (1.6 ± 0.7 vs 1.4 ± 1.0, P = 0.03) and DR3 was associated with higher 
IgA (3.9 ± 2.0 vs 2.9 ± 2.0, P = 0.01) and IgG (16.7 ± 9.4 vs 13.6 ± 8.7, P = 0.051 (not 
significant)).
Extrahepatic autoimmune diseases
There were no significant differences in the rates of extra-hepatic autoimmune diseases between 
groups before or after transplantation (Table 1). Twenty-nine patients (19%) had extra-hepatic 
autoimmune disease before the transplantation: autoimmune thyroiditis (n = 14), rheumatic 
conditions (n = 8) and others (n = 12; type 1 diabetes, ulcerative colitis, celiac disease, multiple 
sclerosis, immune thrombocytopenic purpura). Ten patients (7%) were diagnosed with extra-
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Grave’s disease, sarcoidosis, lupus erythematosus disseminatus, polymyalgia rheumatica, immune 
thrombocytopenic purpura and ulcerative colitis; n = 1 for all.
Biopsies after transplantation
Protocol-biopsy results are displayed in Table 3. Of 104 protocol biopsies available, 31 (30%) 
showed no pathology. Mild portal inflammation (grade 1) occurred in 40 (39%), whereas any 
lobular or interface inflammation were seen in 15 (14%) and 10 (10%), respectively. Fibrosis 
grade 1 was seen in 25 (24%) and grade 2-4 in 5 (5%). Mild cholangitis was present in 5 biopsies; 
3 of these also showed graft hepatitis and one had also co-existent anastomotic biliary stricture.
There was less fibrosis in biopsies ≥10 years post-transplant in the AIH group (0%) compared to 
the known non-AIH group (F1 31%, F2+ 15%) and the unknown group (F1 45%, F2+ 5%), P = 
0.01.
Idiopathic graft hepatitis was found in 10 protocol biopsies: 1 in the AIH group (4%), 2 in the 
known non-AIH group (5%) and 6 in the unknown group (14%) (P = 0.48). Only one graft 
hepatitis was diagnosed under corticosteroid treatment (3% vs 13%; P = 0.16). Only one recurrent 
AIH was observed in protocol biopsies in the AIH group. All patients with graft hepatitis 
diagnosed by protocol biopsy were alive at the end of study period and without significant graft 
dysfunction.
Complete protocol biopsy data was available from all patients transplanted since 2008 (N = 42). In 
this group, two patients with AIH (2/9, 22%) developed post-transplant disease recurrence, and 
three (two in the unknown group and one in the known non-AIH group) were diagnosed with mild 
idiopathic graft hepatitis. No de novo AIH was detected in the unknown or the known non-AIH 
groups. 
Rejections
At least one episode of rejection occurred in 68% of AIH patients, 46% of known non-AIH 
patients and 53% of unknown patients (P = 0.73). Patients with at least one episode of rejection 
had higher pretransplant IgA (3.7 ± 2.3 vs 2.6 ± 1.2, P = 0.02) and IgG (16.4 ± 10.2 vs 12.4 ± 6.8, 
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Survival
Patient survival at 1, 5 and 10 years was 90%, 84% and 81% and graft survival 85%, 74% and 
73%, respectively. There were no significant differences between etiology groups in either patient 
or graft survival (Figure 1 and Figure 2). Re-transplantation rates were similar: 8% in the AIH 
group, 13% in the known non-AIH group and 9% in the unknown group (P = 0.8). No pre-
transplant laboratory test or recipient HLA haplotype had any effect on patient or graft survival in 
univariate analysis (data not shown). Indications for re-transplantation were acute or chronic 
rejection (n = 6), biliary complication (n = 4), primary non-function (n = 1) and arterial thrombosis 
(n = 2).
Discussion
Our study found that features suggesting autoimmunity occurs in some patients transplanted for 
ALF of unknown etiology with more frequent positive pANCA and higher IgA and IgG than in 
the known non-AIH group. No patient in the known non-AIH group had elevated IgG. AIH-
associated HLA haplotypes were equally common in the AIH and unknown groups.
The diagnosis of AIH-ALF has remained difficult as there are no acknowledged diagnostic 
criteria. Diagnostic criteria used in different studies differ markedly and show poor concordance 
(Table 4). Due to these differences, comparing findings from different studies is difficult. Our 
study is in line with previous ones showing features compatible with autoimmune etiology in the 
unknown group (4,11,22).
pANCA is frequently present in type 1 AIH (23), and in UC and PSC. We observed high 
prevalence of pANCA in our AIH group (74%) and also in the unknown group (36%). We had no 
patients diagnosed with AIH-PSC overlap and only two patients had ulcerative colitis. We have 
found no previous studies reporting the prevalence of pANCA in the setting of ALF, only a single 
patient report where pANCA was initially the only detectable antibody in acute-onset AIH (24). 
Our results indicate a role for pANCA in the diagnostic evaluation of AIH-ALF.
The unknown group had a similar prevalence of AIH-associated HLA haplotypes as the AIH 
group, which further supports the hypothesis of autoimmune pathogenesis in some patients in the 
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B8-DR3 and A1-B8-DR3 in ALF patients of unknown etiology, but could not conclude if these 
haplotypes predispose patients to ALF per se or if they are specific to unknown etiology only. Our 
results suggest that certain HLA haplotypes predispose patients only to ALF of unknown and 
autoimmune etiology, not to other etiologies. Interestingly, these haplotypes still showed only 
subtle correlation with pretransplant IgG and no correlation with clinical outcomes. HLA 
haplotypes DR3 and DR4 are associated with greater risk of AIH recurrence after transplantation 
for AIH (13), but as we found only a few cases of recurrent disease in the follow-up, we cannot 
conclude if this also applies to AIH-ALF.
Classical AIH responds well to corticosteroid treatment (25), but results are less encouraging in 
the context of AIH-ALF (26). Recognizing these patients early enough may be key to success as 
patients who reach high MELD-scores may no longer benefit from corticosteroid treatment (8,27). 
Our findings may help to recognize patients who are likely to have an autoimmune etiology of 
ALF and might benefit from a trial of corticosteroid treatment. However, as EASL recommends, a 
trial of corticosteroids should not last for more than seven days if response is not observed (28).
As reported earlier, only a minority of protocol biopsies were completely “normal” (21). Mild 
portal inflammation and fibrosis were frequent, but high inflammatory activity and fibrosis were 
rare. Biopsy results were fairly similar among the etiology groups, and protocol biopsies did not 
reveal any signs of original etiology of unknown ALF. We observed a low incidence of graft 
hepatitis in our ALF patients compared to previous reports, which noted graft hepatitis incidences 
up to 53-71% in the unknown ALF group (5,14). Differences in immunosuppression regimens and 
post-transplantation biopsy interpretation may explain these differences (21,29). 
The etiology of ALF did not affect patient or graft survival. Patients received different type of 
immunosuppression according to etiology, rejections and biopsy findings, and it is impossible to 
evaluate how this might have affected survival. Still, it appears that signs of autoimmunity do not 
have an influence on prognosis after ALF. 
Strengths of our study include a large single center experience of all 152 patients transplanted for 
ALF in an entire country, uniform diagnostic methods and perioperative and post-transplantation 
care including protocol biopsies. Coverage of post-transplantation follow-up was nearly almost 
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The retrospective setting is the main weakness of our study. However, due to rarity of ALF 
leading to liver transplantation, prospective studies are practically non-existent. We did not re-
evaluate liver biopsies for this study, but they were originally reviewed by an experienced liver 
pathologist in multidisciplinary meetings. Applying the SCD-AIH criteria, we found high 
prevalence of AIH in our patients (20%), compared to 5% reported in the US and Spain (30,31). 
This is probably due to few acetaminophen intoxications and viral hepatitis leading to 
transplantation, which is in contrast to many centres where these are the most common causes of 
ALF. Recent study showed that prevalence of “classic” AIH in Finland (14 / 100 000) is 
comparable with other European countries (32).
In conclusion, we found some features compatible with autoimmune etiology in the unknown ALF 
group. These features had still only minor effect on post-transplant biopsy findings and 
complications, and no effect on survival. As we found no clear-cut cases of AIH in the grafts of 
patients transplanted due to unknown etiology, these patients will probably not benefit from AIH-
targeted post-transplantation immunosuppressive regimens.
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Table 1. Clinical and laboratory data of the patients 
   
Etiology 




Unknown P All 
P Known vs 
Unknown 





   SCD-AIH-score, mean ±SD 6.2  ± 0.9 2.4  ± 1.0 3.1 ± 1.0 0.001 0.14 
Female 21 84 % 34 63 % 31 69 % 0.17 0.67 
Age at Tday, years, mean ±SD 51  ± 13 43 ± 14 46 ± 12 0.04 0.40 
Diagnosis-Tday (days) 38 ± 36 22 ± 24 32 ± 35 0.02 0.04 
MELD at Tday 29.8 ± 7.5 29.1 ± 7.8 29.2 ± 7.3 0.81 0.86 
S-ANA positive (≥ 1:80) (n) 23 92 % 10 26 % 14 31 % 0.001 0.63 
S-pANCA positive (≥ 1:10) (n) 14 74 % 2 8 % 11 36 % 0.001 0.02 
S-cANCA positive (≥ 1:10) (n) 6 30 % 5 19 % 2 6 % 0.06 0.22 
P-IgA above ULN¹ (n) 13 52 % 2 7 % 12 27 % 0.001 0.001 
P-IgA (mean), g/l, ±SD 4.7 ± 2.3 2.1 ± 1.4 3.2 ± 1.7 0.001 0.006 
P-IgM above ULN² (n) 2 8 % 1 3 % 5 11 % 0.57 0.39 
P-IgM (mean), g/l, ±SD 1.7 ± 1.2 1.0 ± 0.6 1.6 ± 0.8 0.001 0.001 
P-IgG above ULN³ (n) 23 92 % 0 0 % 9 20 % 0.001 0.04 
P-IgG (mean), g/l, ±SD 25.7 ± 10.2 8.5 ± 3.6 12.7 ± 4.3 0.001 0.001 
S-SMA positive (≥ 1:40) (n) 11 44 % 5 14 % 3 7 % 0.001 0.46 
S-AMA positive (n) 0 0 % 2 5 % 5 11 % 0.18 0.45 
Extrahepatic autoimmune 
disease diagnosed before 
Tday, (n) 5 20 % 11 20 % 10 22 % >0.99 >0.99 
Extrahepatic autoimmune 
disease diagnosed after Tday 
(n) 4 16 % 3 6 % 2 4 % 0.19 >0.99 
ALF presentation 
        Hyperacute (0-7d) 1 4 % 18 33 % 6 13 % 
  Acute (1-4w) 14 56 % 22 41 % 23 51 % 0.02 0.07 
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¹ ULN: 4.84g/l for men, 4.02g/l for women 
     ² ULN: 2.59g/l for men, 2.84g/l for women 
     ³ ULN: 15g/l 
 
 
        Abbreviations: SCD-AIH, simplified criteria for the diagnosis of autoimmune hepatitis; Tday, transplantation 
day; ANA, antinuclear antibodies; S-pANCA, perinuclear antineutrophil cytoplasmic antibodies; S-cANCA, 
cytoplasmic antineutrophil cytoplasmic antibodies; P-Ig, immunoglobulin; S-SMA, smooth muscle antibodies; 
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Table 2. HLA analysis of the study population 
     
 
ALF AIH Known Unknown Population P all P U vs K ¹ P U vs K ² P U vs P ³ P U vs P ⁴ 
B8 23 % 40 % 11 % 29 % 17 % 0.001 0.04 0.23 0.04 0.25 
DR3 28 % 44 % 17 % 33 % 18 % 0.001 0.06 0.38 0.02 0.11 
B8DR3 23 % 36 % 11 % 29 % 8 % 0.001 0.04 0.23 0.001 0.001 
A1B8DR3 15 % 24 % 7 % 20 % - 0.16 0.08 0.47 - - 
DR4 25 % 28 % 22 % 25 % 27 % 0.98 0.86 > 0.99 0.64 > 0.99 
DR13 18 % 8 % 17 % 24 % 23 % 0.22 0.45 > 0.99 0.72 > 0.99 
           ¹ Unknown vs known non-AIH 
       ² Unknown vs known non-AIH, Bonferroni correction 
     ³ Unknown vs general population 
      ⁴ Unknown vs general population, Bonferroni correction 
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Table 3. Protocol biopsies 
         
   
1 year (N = 22) 
 
5 year (N = 34) 
 
10+ year (N = 48) P 
  
AIH Known Unknown AIH Known Unknown AIH Known Unknown 
 Portal 0 1 (25%) 2 (22%) 3 (38%) 4 (57%) 8 (62%) 5 (42%) 8 (67%) 7 (50%) 11 (52%) P = 0.72 for 1 year 
Inflammation 1 2 (50%) 5 (56%) 5 (63%) 3 (43%) 4 (31%) 6 (50%) 4 (33%) 6 (43%) 5 (24%) P = 0.89 for 5 year 
 
2+ 1 (25%) 2 (22%) 0 (0%) 0 (0%) 1 (8%) 1 (8%) 0 (0%) 1 (7%) 5 (24%) P = 0.33 for 10+ year 
  
                  
 
Lobular 0 2 (50%) 6 (75%) 7 (88%) 6 (100%) 12 (92%) 9 (75%) 11 (92%) 
13 
(93%) 17 (81%) P = 0.46 for 1 year 
Inflammation 1 2 (50%) 1 (13%) 1 (13%) 0 (0%) 1 (85) 3 (25%) 1 (8%) 1 (7%) 3 (14%) P = 0.39 for 5 year 
 
2+ 0 (0%) 1 (13%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (5%) P = 0.93 for 10+ year 
  
                  
 
Interface 0 3 (75%) 8 (89%) 7 (88%) 7 (100%) 12 (92%) 11 (92%) 11 (92%) 
13 
(93%) 18 (86%) P = 0.73 for 1 year 
Inflammation 1 0 (0%) 0 (0%) 1 (13%) 0 (0%) 1 (8%) 0 (0%) 1 (85) 1 (7%) 3 (14%) P > 0.99 for 5 year 
 
2+ 1 (25%) 1 (11%) 0 (0%) 0 (0%) 0 (0%) 1 (8%) 0 (0%) 0 (0%) 0 (0%) P = 0.85 for 10+ year 
  
                  
 Fibrosis 0 2 (50%) 8 (89%) 4 (50%) 5 (71%) 11 (85%) 9 (75%) 12 (100%) 7 (54%) 10 (50%) P = 0.25 for 1 year 
 
1 2 (50%) 1 (11%) 3 (38%) 2 (29%) 2 (15%) 2 (17%) 0 (0%) 4 (31%) 9 (45%) P = 0.78 for 5 year 
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Table 4. Diagnostic criteria for AIH-ALF in different studies. 
Study AIH-ALF diagnostic criteria Patients (n) Considerations 
Kessler et al 2004 IAIHG 1999 10 AIH-ALF AIH-ALF patients have poor corticosteroid response compared to non-ALF AIH patients 
Wigg et al 2005 
Exclusion: No history of AIH, absence 
of strongly positive autoantibodies (≥ 
1:100) or a marked IgG elevation and 





More chronic hepatitis in 1-year biopsies in the seronegative group (53% vs 15%) 
compared to known non-AIH etiologies 
Bernal et al 2007 IAIHG 1999 
14 cryptogenic 
ALF 
50% of cryptogenic patients classified as probable or definite AIH 
Ichai et al 2007 
2 / 3 of : 1) autoantibodies at 
significant titers; 2) gamma globulin 
levels above 20 gm/L; or 3) liver 
biopsy revealing features compatible 
with chronic hepatitis 
16 AIH-ALF Corticosteroids usually ineffective in the setting of AIH-ALF 
Yeoman et al 2009 IAIHG 1999 and IAIHG SDC 70 ALF 
Concordance of the IAIHG 1999 criteria and the simplified criteria only 46% in ALF 
patients. Patients with AI by clinical perceptions, 50% identified as AIH by the IAIHG 
SDC and 60% by the IAIHG 1999 criteria 
Stravitz et al 2011 





Histologic score combined with positive autoantobodies (but not the IAIHG SDC) 
associated with increased prevalence of chronic hepatitis. 42% of patients had 
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Karkhanis et al 
2014 
By histology (when available) and ANA 
and anti- smooth muscle antibody 
361 ALF 
Reassigment according to Stravitz et al : 12% of AIH classified as indeterminate. 16% of 
indeterminate classified as AIH. Corticosteroids not beneficial regardless of the etiology 
IAIHG 1999: review of criteria for diagnosis of autoimmune hepatitis (33) 
IAIHG SDC: simplified diagnostic criteria for the diagnosis of autoimmune hepatitis (15) 
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